Open AccessDipeptidyl peptidase‐4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase ‐4抑制剂：多靶点药物，不仅仅是降糖药)
Author(s) -
Zhao Yunjuan,
Yang Lin,
Zhou Zhiguang
Publication year - 2014
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12063
Subject(s) - dipeptidyl peptidase 4 , dipeptidyl peptidase , medicine , incretin , pharmacology , context (archaeology) , glucagon like peptide 1 , immune system , diabetes mellitus , enzyme , type 2 diabetes , endocrinology , biochemistry , immunology , biology , paleontology
Dipeptidyl peptidase ( DPP )‐4 inhibitors are a new class of antidiabetic agents that reduce blood glucose by preventing the degradation of the endogenous incretin hormones glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide. Protection by DPP ‐4 inhibitors of β‐cell function has been demonstrated in patients with type 2 diabetes. Because DPP ‐4 is an enzyme widely expressed in humans, DPP ‐4 inhibitors are speculated to be multitarget agents. However, other potential therapeutic benefits of DPP ‐4 inhibitors remain unknown. Recently, some therapeutic effects of DPP ‐4 inhibitors, such as immune regulation, cardiovascular protection, and anti‐inflammatory effects, have been observed. This article provides a systematic and comprehensive review of current research into the newly found effects and mechanism of action of DPP ‐4 inhibitors in a therapeutic context.